佛慈制药涨2.14%，成交额4406.80万元，主力资金净流入83.41万元

Group 1 - The core viewpoint of the news is that 佛慈制药 has shown a positive stock performance with a year-to-date increase of 23.77% and a recent rise in trading activity, indicating potential investor interest [1][2] - As of November 14, 佛慈制药's stock price reached 9.54 yuan per share, with a market capitalization of 4.872 billion yuan and a trading volume of 44.068 million yuan [1] - The company has experienced net inflows of 834,100 yuan from major funds, with significant buying and selling activity noted in recent trading sessions [1] Group 2 - 佛慈制药's main business includes the research, production, and sales of traditional Chinese medicine, health products, and medical devices, with 99.41% of its revenue coming from these areas [1] - As of September 30, the number of shareholders increased by 8.23% to 33,300, while the average circulating shares per person decreased by 7.61% to 15,340 shares [2] - For the period from January to September 2025, 佛慈制药 reported a revenue of 624 million yuan, a year-on-year decrease of 11.92%, and a net profit attributable to shareholders of 38.0824 million yuan, down 2.54% year-on-year [2] Group 3 - 佛慈制药 has distributed a total of 180 million yuan in dividends since its A-share listing, with 46.9804 million yuan distributed over the past three years [3]